Navigation
Home
Advocating for Access
Background
Letters for Access
Press Releases For Access
Simplified Community Materials
Simplified Community Materials
Understanding your HCV infection
Community Led Reports
Country Information
Indonesia
India
Vietnam
Generic DAAs Pricing
Resources
Guidelines
Key Research Publication
Other Important Documents and Reports
News
Gallery
Photos
Video
Stories
Response from CEO, CHAI about the Quick Start program in November 2016
Response from CEO, CHAI about the Quick Start program in November 2016
Please click here
December 21, 2016
/
News
Share
the Post
Related
Posts
BMS’ patent bid for Hep C treatment Daclatasvir Challenged
Know the interactions between HIV and Hep C medicines
Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
Asia-Pacific Aids Groups Express Deep Dismay At Conclusion Of Secretly Negotiated Trans-Pacific Partnership Agreement That Threatens Future Access To Affordable Generic Medicines And Sustainable Development Goals
New WHO guideline on care and treatment of chronic hepatitis C
Patent Situation of The Key Product for Treatment of Hepatitis C: DACLASTAVIR – WHO working paper, revised version, Oct 2014
Availability and Pricing of Generic Sofosbuvir in India – Updated 10 September 2015
Strategies to Secure Access to Generic HCV Medicines
